Discussion
Leukemia is a heterogeneous group of malignant clonal diseases of the
hematopoietic tissue belonging to the group of hemoblastoses.
Pathological disorders in the bone marrow lead to secondary
immunodeficiency, as a result of which the disease becomes systemic.
According to Chinese researchers, patients with cancer have worse
outcomes from COVID-19, which suggests that this group should be given
more attention (12). Three main strategies are proposed for patients
with cancer during the COVID-19 pandemic and in the event of severe
infectious complications. First, in endemic regions, consideration
should be given to deferring chemotherapy and routine hospitalization.
Secondly, more stringent personal protection measures for cancer
patients should be envisaged. Third, more intensive monitoring or
treatment should be considered when patients are infected with
SARS-CoV-2 (12). The department for the treatment of patients with
hematological malignancies with concomitant COVID-19 has been operating
since June 2020. During this period, 19 patients were treated, of which:
men - 11, women - 8. The average age was 43 years (+-16). Of these,
patients with multiple myeloma-32%; acute myeloid leukemia - 26%;
acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia -
26%; chronic lymphocytic leukemia - 5%. In our center, we have chosen
the tactics of conducting complex therapy for patients with
hemoblastosis and hematopoietic depression with COVID-19 without
interrupting chemotherapy. According to our preliminary observation,
chemotherapy does not worsen the course of COVID-19 and does not
increase early mortality after chemotherapy.